| Symbol |
DRD1 |
| Full Name |
Dopamine Receptor D1 |
| Chromosome |
5q35.2 |
| NCBI Gene |
1817 |
| Ensembl |
ENSG00000184845 |
| UniProt |
P21709 |
| Diseases |
[Parkinson's Disease](/diseases/parkinsons-disease), [Schizophrenia](/diseases/schizophrenia), [Huntington's Disease](/diseases/huntingtons) |
| Expression |
Striatum, Cortex, Nucleus accumbens, Olfactory bulb |
Drd1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DRD1 (Dopamine Receptor D1) encodes the D1 dopamine receptor, a G protein-coupled receptor that stimulates adenylyl cyclase and increases intracellular cAMP. It is the most abundant dopamine receptor in the striatum and plays critical roles in motor control, reward, and cognition.
The D1 receptor is a postsynaptic dopamine receptor that:
- Gs/olf coupling: Activates adenylyl cyclase → increases cAMP
- PKA activation: Phosphorylates DARPP-32 and other targets
- Gene transcription: Modulates CREB-mediated transcription
- ERK/MAPK activation: Downstream signaling cascades
- Beta-arrestin pathways: G protein-independent signaling
- Motor control: Direct pathway activation in basal ganglia
- Reward processing: Mediates dopamine's rewarding effects
- Cognition: Working memory and attention
- Motor learning: Habit formation and procedural memory
- Endocrine regulation: Modulates prolactin secretion
The D1 receptor interacts with multiple proteins:
- G proteins: Gs, Golf (striatum-specific)
- DARPP-32: Phosphoprotein that amplifies D1 signaling
- AKAP79: Anchors PKA to the membrane
- beta-arrestin 2: Mediates desensitization and alternative signaling
- NMDA receptors: Regulation of glutamatergic transmission
- DRD1 agonists used therapeutically
- Loss of D1-expressing neurons in PD
- D1 dysfunction contributes to akinesia
- D1 hypofunction theory of cognitive deficits
- D1 agonists may improve working memory
- Interactions with antipsychotic drugs
- Early loss of D1 receptors
- Contributes to chorea and cognitive deficits
- D1 agonists being explored therapeutically
- D1 receptors modulate hippocampal plasticity
- Potential role in memory consolidation
- Interactions with amyloid pathology
- Cognitive effects of D1 modulation
- D1-mediated cAMP can increase neuronal energy demands
- Potential for excitotoxic vulnerability in PD
- Interactions with glutamatergic signaling
- Dopamine metabolism produces ROS
- D1 signaling may modulate antioxidant responses
- Vulnerability of D1 neurons in PD
- D1 receptors on microglia regulate inflammation
- Anti-inflammatory effects of D1 activation
- Implications for PD and AD pathogenesis
| Drug Class |
Examples |
Indication |
| D1 agonists |
Aplindore, PF-06412562 |
PD, Restless legs |
| D1 partial agonists |
Sumarampion |
Potential cognitive enhancer |
- D1 agonists: rotate to D1-selective agents under development
- combination therapy with D2 agonists
- Deep brain stimulation affects D1-expressing neurons
- A71113 being investigated for cognitive enhancement
- D1 agonists for working memory deficits in schizophrenia
- Potential for dystonia treatment
- Activates adenylyl cyclase
- Increases cAMP
- Activates PKA
- Phosphorylates DARPP-32 (enhances D2 inhibition)
- D1 can signal through beta-arrestin pathways
- G protein-independent signaling
- Role in D1-mediated behaviors
- Highest in striatum (direct pathway neurons)
- Cortex (layer V pyramidal neurons)
- Hippocampus
- Substantia nigra pars reticulata
- Olfactory bulb
¶ Protein Structure and Pharmacology
- Seven transmembrane domain GPCR
- Extracellular N-terminus for ligand binding
- Intracellular C-terminus for G protein coupling
- Conserved DRY motif for G protein activation
¶ Ligand Binding
- Endogenous ligand: dopamine
- Agonists: higher efficacy at D1
- Antagonists: typical antipsychotics
- Partial agonists: some experimental compounds
- DRD1 polymorphisms not strongly associated with PD risk
- Haplotypes may influence drug response
- Interaction with other PD risk genes
- DRD1 associations with attention deficit hyperactivity disorder
- Pharmacogenetic considerations for stimulant therapy
- D1 antagonists reduce tics
- Direct pathway hyperactivity model
- Deep brain stimulation targeting D1 neurons
- D1 agonists for Parkinson's disease motor symptoms
- Potential for cognitive enhancement
- Dyskinesia management strategies
- Combination with D2 therapies
- D1 receptor density imaging (PET)
- Gene expression studies
- CSF biomarkers
- Drd1 knockout mice show reduced locomotor activity
- Impaired reward learning
- Learning and memory deficits
- D1 overexpression: enhanced locomotion
- Constitutively active D1: hyperactive behaviors
- Cre driver lines for conditional deletion
- 6-OHDA lesion: D1 expression changes
- MPTP model: D1 dysfunction
- Transgenic AD models: D1 interactions
- D1-selective agonists with better pharmacokinetics
- Allosteric modulators for subtype specificity
- biased signaling - G protein vs beta-arrestin
- PET ligands for D1 imaging
- How does D1 signaling differ in aging vs PD?
- Can D1 modulators slow neurodegeneration?
- What determines individual drug response?
- How do D1/D2 interactions affect circuit function?
The direct pathway is the "go" pathway:
- Cortex sends excitatory projections to striatum
- D1-expressing striatal neurons (direct pathway) receive this input
- These neurons project to substantia nigra pars reticulata (SNr) and GPi
- Direct pathway activation inhibits SNr/GPi, reducing thalamic inhibition
- This facilitates movement initiation and execution
The indirect pathway involves D2 receptors:
- Cortex excites striatal D2 neurons
- D2 neurons project to external globus pallidus (GPe)
- GPe inhibits subthalamic nucleus (STN)
- STN excites SNr/GPi
- This pathway inhibits movement
- D1 neurons receive input from sensorimotor cortex
- D1 and D2 neurons are intermingled in striatum
- D1 neurons have longer dendritic spines (接收更多兴奋性输入)
- D1 signaling enhances signal-to-noise in direct pathway